Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
dc.contributor.author | Abi-Saab, Danielle | en_US |
dc.contributor.author | Krystal, John H. | en_US |
dc.contributor.author | Bremner, J. Douglas | en_US |
dc.contributor.author | Charney, Dennis S. | en_US |
dc.contributor.author | Karper, Laurence P. | en_US |
dc.contributor.author | Bennett, Alexandre | en_US |
dc.contributor.author | Stetson, Philip L. | en_US |
dc.contributor.author | Morrissey, Kristen | en_US |
dc.contributor.author | Suckow, Raymond F. | en_US |
dc.contributor.author | D’souza, D. Cyril | en_US |
dc.contributor.author | Bowers Jr. , M. B. | en_US |
dc.contributor.author | Abi-Dargham, Anissa | en_US |
dc.contributor.author | Heninger, George R. | en_US |
dc.date.accessioned | 2006-09-08T19:49:14Z | |
dc.date.available | 2006-09-08T19:49:14Z | |
dc.date.issued | 1998-01 | en_US |
dc.identifier.citation | Krystal, John H.; Karper, Laurence P.; Bennett, Alexandre; D’Souza, D. Cyril; Abi-Dargham, Anissa; Morrissey, Kristen; Abi-Saab, Danielle; Bremner, J. Douglas; Bowers Jr., M. B.; Suckow, Raymond F.; Stetson, Philip; Heninger, George R.; Charney, Dennis S.; (1998). "Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans." Psychopharmacology 135(3): 213-229. <http://hdl.handle.net/2027.42/41959> | en_US |
dc.identifier.issn | 0033-3158 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41959 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9498724&dopt=citation | en_US |
dc.description.abstract | Ketamine is an N -methyl- D -aspartate (NMDA) receptor antagonist with psychotogenic and dissociative effects in healthy humans. These cognitive and perceptual effects in humans are reportedly reduced by benzodiazepine premedication. This study assessed the interactive effects of a ketamine (IV bolus of 0.26 mg/kg followed by an infusion of 0.65 mg/kg per hour) and lorazepam 2 mg., PO, in humans. Twenty-three healthy subjects completed 4 test days involving the oral administration of lorazepam or matched placebo 2 h prior to the IV infusion of ketamine or placebo. Ketamine: 1) produced behaviors similar to the positive and negative symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale (BPRS); 2) evoked perceptual alterations as measured by the Clinician-Administered Dissociative States Scale (CADSS); 3) impaired performance on the Wisconsin Card Sorting Test (WCST) and other tests sensitive to frontal cortical impairment; and 4) had amnestic effects. Lorazepam produced attention impairments, concrete proverb interpretations, and recall impairments. Lorazepam reduced ketamine-associated emotional distress and there was a non-significant trend for it to decrease perceptual alterations produced by ketamine. However, it failed to reduce many cognitive and behavioral effects of ketamine, including psychosis. Further, lorazepam exacerbated the sedative, attention-impairing, and amnestic effects of ketamine. There was no evidence of pharmacokinetic interaction between these medications. These data suggest that subhypnotic lorazepam and ketamine show a spectrum of interactive effects, ranging from antagonism to potentiation. | en_US |
dc.format.extent | 728770 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Key Words Ketamine | en_US |
dc.subject.other | Attention | en_US |
dc.subject.other | Frontal Cortex | en_US |
dc.subject.other | Psychosis | en_US |
dc.subject.other | Memory | en_US |
dc.subject.other | Benzodiazepine | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | GABA | en_US |
dc.subject.other | N-methyl-D-aspartate | en_US |
dc.subject.other | Glutamate | en_US |
dc.subject.other | Dissociation | en_US |
dc.subject.other | Wisconsin Card Sorting Test | en_US |
dc.title | Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Upjohn Center for Clinical Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109-0504, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Psychiatry Service (116-A), VA Medical Center, West Haven, CT 06516, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | New York State Psychiatric Institute, 722 W. 168th Street, New York, NY 10032, USA, US, | en_US |
dc.contributor.affiliationother | Psychiatry Service (116-A), VA Medical Center, West Haven, CT 06516, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Yale University School of Medicine, Connecticut, USA, US, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 9498724 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41959/1/213-135-3-213_81350213.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002130050503 | en_US |
dc.identifier.source | Psychopharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.